Products
Anivovetmab Biosimilar Canine Monoclonal Antibody (Canine Parvovirus VP2) for Research
Cat No.: GMP-Bios-INN-1080
Anti-Minor Capsid VP2 (Canine) therapeutic antibody (Pre-made Anivovetmab biosimilar,Canine Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Anivovetmab (development code KIND030) is a canine monoclonal antibody targeting canine parvovirus major capsid protein VP2. It is developed by Kindred Biosciences for canine parvovirus.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1080-1mg | 1mg | 3090 |
| GMP-Bios-INN-1080-10mg | 10mg | |
| GMP-Bios-INN-1080-100mg | 100mg | |
| GMP-Bios-INN-1080-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Anivovetmab biosimilar, Canine Whole mAb: Anti-Minor Capsid VP2 (Canine) therapeutic antibody |
| INN Name | Anivovetmab |
| Target | Minor Capsid VP2 (Canine) |
| Format | Canine Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Canine |
| CH1+2+3 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 3iy6:BA/3jcx:HL |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Kindred Biosciences |
| Conditions Approved | na |
| Conditions Active | Canine parvovirus |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
